Oral administration of poly-γ-glutamate ameliorates atopic dermatitis in Nc/Nga mice by suppressing Th2-biased immune response and production of IL-17A

Journal of Investigative Dermatology

Volumn 134, Issue 3, 2014, Pages 704-711

  Lee, Tae Young ^a   Kim, Doo Jin ^a   Won, Ji Na ^a   Lee, Il Han ^b   Sung, Moon Hee ^c   Poo, Haryoung ^a  

^a Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

^b Bioleaders Corporation   (South Korea)

^c Kookmin University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; B7 ANTIGEN; CD40 ANTIGEN; CD86 ANTIGEN; CONCANAVALIN A; DEXAMETHASONE; GAMMA INTERFERON; GLUTAMIC ACID DERIVATIVE; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 4; INTERLEUKIN 5; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; POLY GAMMA GLUTAMATE; UNCLASSIFIED DRUG; POLYGAMMA GLUTAMATE; POLYGLUTAMIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ATOPIC DERMATITIS; CELL DIFFERENTIATION; CONTROLLED STUDY; DENDRITIC CELL; DERMATITIS; DRUG EFFECT; DRUG MEGADOSE; DRUG RESPONSE; IMMUNE RESPONSE; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOHISTOLOGY; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO STUDY; LOW DRUG DOSE; MALE; MAST CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SKIN DEFECT; SPLEEN CELL; TH17 CELL; TH2 CELL; TREATMENT DURATION; UPREGULATION; ANTINEOPLASTIC ACTIVITY; CYTOKINE PRODUCTION;

ADMINISTRATION, ORAL; ANIMALS; DENDRITIC CELLS; DERMATITIS, ATOPIC; DERMATOLOGIC AGENTS; DISEASE MODELS, ANIMAL; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; INTERLEUKIN-12; INTERLEUKIN-17; MALE; MAST CELLS; MICE; MICE, INBRED C57BL; MICE, MUTANT STRAINS; POLYGLUTAMIC ACID; TH2 CELLS;

EID: 84894101811     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2013.389     Document Type: Article

References (50)

1. Agarwal SK, Marshall GD Jr (2001) Dexamethasone promotes type 2 cytokine production primarily through inhibition of type 1 cytokines. J Interferon Cytokine Res 21:147-555
2. Arellano FM, Wentworth CE, Arana A et al. (2007) Risk of lymphoma following exposure to calcineurin inhibitors and topical steroids in patients with atopic dermatitis. J Invest Dermatol 127:808-166
3. Barnetson RS, White AD (1992) The use of corticosteroids in dermatological practice. Med J Aust 156:428-311
4. Bornhovd E, Burgdorf WH, Wollenberg A (2001) Macrolactam immunomodulators for topical treatment of inflammatory skin diseases. J Am Acad Dermatol 45:736-433
5. Buescher JM, Margaritis A (2007) Microbial biosynthesis of polyglutamic acid biopolymer and applications in the biopharmaceutical, biomedical and food industries. Crit Rev Biotechnol 27:1-199
6. Candela T, Fouet A (2006) Poly-gamma-glutamate in bacteria. Mol Microbiol 60:1091-88
7. Charman C, Williams H (2003) The use of corticosteroids and corticosteroid phobia in atopic dermatitis. Clin Dermatol 21:193-2000
8. Clark MA, Blair H, Liang L et al. (2001) Targeting polymerised liposome vaccine carriers to intestinal M cells. Vaccine 20:208-177
9. Crabtree GR (2001) Calcium, calcineurin, and the control of transcription. J Biol Chem 276:2313-66
10. Foster N, Clark MA, Jepson MA et al. (1998) Ulex europaeus 1 lectin targets microspheres to mouse Peyer's patch M-cells in vivo. Vaccine 16:536-411
11. Gebert A, Rothkotter HJ, Pabst R (1996) M cells in Peyer's patches of the intestine. Int Rev Cytol 167:91-1599
12. Hamid Q, Boguniewicz M, Leung DY (1994) Differential in situ cytokine gene expression in acute versus chronic atopic dermatitis. J Clin Invest 94:870-66
13. Hattori K, Nishikawa M, Watcharanurak K et al. (2010) Sustained exogenous expression of therapeutic levels of IFN-gamma ameliorates atopic dermatitis in NC/Nga mice via Th1 polarization. J Immunol 184:2729-355
14. Horiuchi Y, Bae S, Katayama I et al. (2004) Therapeutic effects of streptococcal preparation OK-432 on atopic dermatitis-like lesions in NC/Nga mice: possible shift from a Th2- to Th1-predominance. J Dermatol Sci 35:187-977
15. Howell MD, Kim BE, Gao P et al. (2007) Cytokine modulation of atopic dermatitis filaggrin skin expression. J Allergy Clin Immunol 120:150-55
16. Hughes J, Rustin M (1997) Corticosteroids. Clin Dermatol 15:715-211
17. Inoue J, Aramaki Y (2007) Suppression of skin lesions by transdermal application of CpG-oligodeoxynucleotides in NC/Nga mice, a model of human atopic dermatitis. J Immunol 178:584-911
18. Jepson MA, Simmons NL, O'Hagan DT et al. (1993) Comparison of poly(DLlactide- co-glycolide) and polystyrene microsphere targeting to intestinal M cells. J Drug Target 1:245-99
19. Kim CH, Choi YS, Cheong KA et al. (2013) Mechanism underlying the effect of combined therapy using glucosamine and low-dose cyclosporine A on the development of atopic dermatitis-like skin lesions in NC/Nga mice. Int Immunopharmacol 15:424-322
20. Kim TW, Lee TY, Bae HC et al. (2007) Oral administration of high molecular mass poly-gamma-glutamate induces NK cell-mediated antitumor immunity. J Immunol 179:775-800
21. Kocianova S, Vuong C, Yao Y et al. (2005) Key role of poly-gamma-DL-glutamic acid in immune evasion and virulence of Staphylococcus epidermidis. J Clin Invest 115:688-944
22. Koga C, Kabashima K, Shiraishi N et al. (2008) Possible pathogenic role of Th17 cells for atopic dermatitis. J Invest Dermatol 128:2625-300
23. Kohara Y, Tanabe K, Matsuoka K et al. (2001) A major determinant quantitative-trait locus responsible for atopic dermatitis-like skin lesions in NC/Nga mice is located on Chromosome 9. Immunogenetics 53:15-211
24. Kondo K (1973) Improvement and establishment of inbred mouse strain in Japan. Jikken Dobutsu 22(Suppl):271-66
25. Lane PW (1972) Two new mutations in linkage group XVI of the house mouse Flaky tail and varitint-waddler. J Hered 63:135-400
26. Lee TY, Kim YH, Yoon SW et al. (2009) Oral administration of poly-gammaglutamate induces TLR4- and dendritic cell-dependent antitumor effect. Cancer Immunol Immunother 58:1781-944
27. Leung AK, Barber KA (2003) Managing childhood atopic dermatitis. Adv Ther 20:129-377
28. Leung DY (1997) Atopic dermatitis: immunobiology and treatment with immune modulators. Clin Exp Immunol 107(Suppl 1):25-300
29. Leung DY, Soter NA (2001) Cellular and immunologic mechanisms in atopic dermatitis. J Am Acad Dermatol 44:S1-122
30. Lutz MB, Kukutsch N, Ogilvie AL et al. (1999) An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J Immunol Methods 223:77-922
31. Matsuda H, Watanabe N, Geba GP et al. (1997) Development of atopic dermatitis-like skin lesion with IgE hyperproduction in NC/Nga mice. Int Immunol 9:461-66
32. Matsumoto M, Ra C, Kawamoto K et al. (1999) IgE hyperproduction through enhanced tyrosine phosphorylation of Janus kinase 3 in NC/Nga mice, a model for human atopic dermatitis. J Immunol 162:1056-633
33. McAleer MA, Irvine AD (2013) The multifunctional role of filaggrin in allergic skin disease. J Allergy Clin Immunol 131:280-911
34. Milgrom H, Fick RB Jr, Su JQ et al. (1999) Treatment of allergic asthma with monoclonal anti-IgE antibody. rhuMAb-E25 Study Group. N Engl J Med 341:1966-733
35. Moniaga CS, Egawa G, Kawasaki H et al. (2010) Flaky tail mouse denotes human atopic dermatitis in the steady state and by topical application with Dermatophagoides pteronyssinus extract. Am J Pathol 176:2385-933
36. Neutra MR, Frey A, Kraehenbuhl JP (1996) Epithelial M cells: gateways for mucosal infection and immunization. Cell 86:345-88
37. Okamoto S, Yoshii H, Matsuura M et al. (2012) Poly-gamma-glutamic acid nanoparticles and aluminum adjuvant used as an adjuvant with a single dose of Japanese encephalitis virus-like particles provide effective protection from Japanese encephalitis virus. Clin Vaccine Immunol 19:17-222
38. Oppermann-Sanio FB, Steinbuchel A (2002) Occurrence, functions and biosynthesis of polyamides in microorganisms and biotechnological production. Naturwissenschaften 89:11-222
39. Oyoshi MK, Murphy GF, Geha RS (2009) Filaggrin-deficient mice exhibit TH17- dominated skin inflammation and permissiveness to epicutaneous sensitization with protein antigen. J Allergy Clin Immunol 124:485-93. 93 e11
40. Palmer CN, Irvine AD, Terron-Kwiatkowski A et al. (2006) Common loss-offunction variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat Genet 38:441-66
41. Park ST, Kim KE, Na K et al. (2007) Effect of dendritic cells treated with CpG ODN on atopic dermatitis of Nc/Nga mice. J BiochemMol Biol 40:486-933
42. Sampson HA (1992) Atopic dermatitis. Ann Allergy 69:469-799
43. Schreier HJ (1993) In: Sonenshein AL, Hoch JA, Losick R eds Bacillus Subtilis and Other Gram-Positive Bacteria. American Society for Microbiology: Washington, DC, 281-988
44. Spergel JM, Mizoguchi E, Oettgen H et al. (1999) Roles of TH1 and TH2 cytokines in a murine model of allergic dermatitis. J Clin Invest 103:1103-111
45. SungMH, Park C, KimCJ et al. (2005) Natural and edible biopolymer poly-gammaglutamic acid: synthesis, production, and applications. Chem Rec 5:352-666
46. Suto H, Matsuda H, Mitsuishi K et al. (1999) NC/Nga mice: a mouse model for atopic dermatitis. Int Arch Allergy Immunol 120(Suppl 1):70-55
47. Thaiwat S, Sangasapaviliya A (2011) Omalizumab treatment in severe adult atopic dermatitis. Asian Pac J Allergy Immunol (launched by the Allergy and Immunology Society of Thailand) 29:357-600
48. Toda M, Leung DY, Molet S et al. (2003) Polarized in vivo expression of IL-11 and IL-17 between acute and chronic skin lesions. J Allergy Clin Immunol 111:875-811
49. Uto T, Wang X, Sato K et al. (2007) Targeting of antigen to dendritic cells with poly(gamma-glutamic acid) nanoparticles induces antigen-specific humoral and cellular immunity. J Immunol 178:2979-866
50. Vestergaard C, Yoneyama H, Murai M et al. (1999) Overproduction of Th2- specific chemokines in NC/Nga mice exhibiting atopic dermatitis-like lesions. J Clin Invest 104:1097-1055